Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 66 In phase 3a trials semaglutide shows best in-class potential on HbA1c reduction across treatment cascade Comparison of HbA1c lowering effect in SUSTAIN 1, 2, 3, 4 and 5 trials Sema 1 mg Sema 0.5 mg Placebo Sitagliptin 100 mg Exenatide QW % patients HbA1c ≤7% Baseline 0.0 SUSTAIN 1 8.1% SUSTAIN 2 8.1% SUSTAIN 3 8.4% SUSTAIN 4 8.2% Insulin glargine QD SUSTAIN 5 8.4% Change in HbA1c (%) -0.4 -0.8 0.0 -0.5 -1.2 -1.3 -1.5 -1.5 -1.6 -1.6 -1.6 * * -0.9 -1.6 -1.2 -0.8 -1.8 -1.4 -0.1 -2.0 72% 74% 25% 78% 69% 36% 67% 40% 73% 58% 38% 79% 61% 11% *p < 0.001; QD: once daily; QW: once weekly; sema: semaglutide Source: Novo Nordisk on file (NN9535-3623, NN9535-3624, NN9535-3625, NN9535-3626, NN9535-3627) changing diabetes® × novo nordisk

View entire presentation